Claudin-9 is a novel prognostic biomarker for endometrial cancer
Claudin-9 is a novel prognostic biomarker for endometrial cancer
复制标题
DOI：
10.3892/ijo.2022.5425
复制
发表时间：
2022-11-01
影响因子：
5.2
通讯作者：
Chiba, Hideki
中科院分区：
文献类型：
--
作者：
Endo, Yuta;Sugimoto, Kotaro;Chiba, Hideki
紧密连接蛋白claudin-9（CLDN 9）几乎不分布在正常成人组织中，但在各种癌症类型中异位表达。尽管多个数据库表明CLDN 9在mRNA水平上在子宫内膜癌中上调，但其蛋白表达和生物学作用仍然不清楚。在本研究中，CLDN 9的表达在子宫内膜癌的预后意义进行了评估，使用福尔马林固定石蜡包埋标本从248例子宫内膜癌的免疫组化染色和半定量。共43例（17.3%）CLDN 9高表达，而205例（82.7%）CLDN 9低表达。CLDN 9高表达组和低表达组的5年疾病特异性生存率分别为62.8%和87.8%（P
The tight-junction protein claudin-9 (CLDN9) is barely distributed in normal adult tissues but is ectopically expressed in various cancer types. Although multiple databases indicated upregulation of CLDN9 in endometrial cancers at the mRNA level, its protein expression and biological roles remain obscure. In the present study, the prognostic significance of CLDN9 expression in endometrial cancer was evaluated by immunohistochemical staining and semi-quantification using formalin-fixed paraffin-embedded specimens obtained from 248 endometrial carcinoma cases. A total of 43 cases (17.3%) had high CLDN9 expression, whereas 205 cases (82.7%) exhibited low CLDN9 expression. The 5-year disease-specific survival rates in the high and low CLDN9 expression groups were 62.8 and 87.8% (P